754159-68-7 Usage
Uses
Used in Pharmaceutical Industry:
IB-MECA is used as a therapeutic agent for the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Its agonistic action on the adenosine A3 receptor helps in reducing inflammation and alleviating the symptoms associated with these conditions.
Used in Oncology:
IB-MECA is used as an anticancer agent, where it exhibits properties such as inhibiting cell proliferation, reducing inflammation, and promoting apoptosis in cancer cells. Its ability to modulate various signaling pathways involved in cancer progression makes it a promising candidate for cancer therapy.
Used in Drug Development Research:
In the field of drug development, IB-MECA serves as a valuable research tool for studying the role of adenosine A3 receptors in various physiological and pathological processes. Understanding its mechanism of action can aid in the design of novel therapeutic agents targeting this receptor for the treatment of different diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 754159-68-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,5,4,1,5 and 9 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 754159-68:
(8*7)+(7*5)+(6*4)+(5*1)+(4*5)+(3*9)+(2*6)+(1*8)=187
187 % 10 = 7
So 754159-68-7 is a valid CAS Registry Number.
754159-68-7Relevant academic research and scientific papers
PROCESS FOR THE PREPARATION OF FESOTERODINE OR ITS SALTS
-
, (2013/04/13)
The present invention relates to a process for the preparation of fesoterodine or its salts.
PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST
-
, (2012/08/07)
The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.
IMPROVED PROCESS FOR DIPHENYLPROPYLAMINE DERIVATIVES
-
, (2011/12/04)
The present invention relates to an improved process for the preparation of biologically active diphenylpropylamine derivatives. The present invention specifically relates to an improved fesoterodine of formula (I) and its pharmaceutically acceptable salts.
SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES
-
, (2011/06/19)
Provided herein are novel solid state forms of fesoterodine intermediates, (R)-4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid and (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, and processes for their preparation thereof. The solid state intermediates are useful for preparing fesoterodine or a pharmaceutically acceptable salt thereof in high purity.